Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168269 | 0.86 | ADRA2C (0.48) | ALDH1A1ADRA2CHTR3ACTSBCTSS | |
| SCHEMBL4174461 | 0.85 | ALDH1A1 (0.53) | ALDH1A1ADRA2CMAPTKDM4EGAA | |
| SCHEMBL4181970 | 0.76 | SIRT6 (0.46) | ALDH1A1SIRT6CTSBCTSSCTSK | |
| SCHEMBL27761791 | 0.70 | ALDH1A1 (0.41) | ALDH1A1HRH4MAPTGAAHTT | |
| SCHEMBL3588290 | 0.70 | CHKA (0.50) | ALDH1A1KDM4ENCF1LMNA | |
| SCHEMBL18999635 | 0.68 | KDM4E (0.48) | ALDH1A1HRH4ADRA2CMAPTKDM4E | |
| SCHEMBL5556541 | 0.67 | ALDH1A1 (0.57) | ALDH1A1ADRA2CMAPTKDM4EGAA | |
| SCHEMBL3590202 | 0.66 | AGXT (0.43) | ALDH1A1HRH4ADRA2CMAPTKDM4E | |
| SCHEMBL31249650 | 0.66 | ADRA2C (0.51) | ALDH1A1ADRA2CMAPTKMT2AHTR3A | |
| SCHEMBL30434962 | 0.66 | ADRA2C (0.51) | ALDH1A1ADRA2CMAPTKMT2AHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2074127-A1 | PYRAZOLO [1, 5-A]PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | ALDH1A1 4236/4885HRH4 3214/4885ADRA2C 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.